Cargando…
第三代EGFR-TKIs耐药之初探
Targeted therapy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) has been the standard modality as first-line treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). The thirdgeneration EGFR-TKIs has been approved to overcome the EGFR T790M mutation in patien...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973016/ https://www.ncbi.nlm.nih.gov/pubmed/29526178 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.02.02 |